Advances in new antivirals for chronic hepatitis B / 中华医学杂志(英文版)
Chinese Medical Journal
;
(24): 571-583, 2022.
Artículo
en Inglés
| WPRIM
| ID: wpr-927536
ABSTRACT
Chronic hepatitis B virus (HBV) infection remains a global health burden. Timely and effective antiviral therapy is beneficial for patients with HBV infection. With existing antiviral drugs, including nucleos(t)ide analogs and interferon-alfa, patients can achieve viral suppression with improved prognosis. However, the rate of hepatitis B surface antigen loss is low. To achieve a functional cure and even complete cure in chronic hepatitis B patients, new antivirals need to be developed. In this review, we summarized the advantages and disadvantages of existing antiviral drugs and focused on new antivirals including direct-acting antiviral drugs and immunotherapeutic approaches.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Antivirales
/
Virus de la Hepatitis B
/
Hepatitis B Crónica
/
Hepatitis C Crónica
/
Hepatitis B
/
Antígenos de Superficie de la Hepatitis B
Límite:
Humanos
Idioma:
Inglés
Revista:
Chinese Medical Journal
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS